Oncopeptides Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Oncopeptides şirketinin toplam hissedar öz sermayesi SEK193.0M ve toplam borcu SEK114.9M olup, bu da borç-öz sermaye oranını 59.5% seviyesine getiriyor. Toplam varlıkları ve toplam yükümlülükleri sırasıyla SEK452.9M ve SEK260.0M dir.

Anahtar bilgiler

59.5%

Borç/özkaynak oranı

SEK 114.89m

Borç

Faiz karşılama oranı	n/a
Nakit	SEK 383.28m
Eşitlik	SEK 192.96m
Toplam yükümlülükler	SEK 259.96m
Toplam varlıklar	SEK 452.92m

Son finansal sağlık güncellemeleri

Recent updates

An Intrinsic Calculation For Oncopeptides AB (publ) (STO:ONCO) Suggests It's 45% Undervalued

Jun 18

Oncopeptides (STO:ONCO) Will Have To Spend Its Cash Wisely

Feb 29

Oncopeptides (STO:ONCO) Has Debt But No Earnings; Should You Worry?

Nov 14

We Think Oncopeptides (STO:ONCO) Needs To Drive Business Growth Carefully

Jul 26

Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?

Mar 25

Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?

Nov 23

Finansal Durum Analizi

Kısa Vadeli Yükümlülükler: ONCO 'nin kısa vadeli varlıkları ( SEK420.6M ) kısa vadeli yükümlülüklerini ( SEK121.0M ) aşıyor.

Uzun Vadeli Yükümlülükler: ONCO şirketinin kısa vadeli varlıkları ( SEK420.6M ) uzun vadeli yükümlülüklerini ( SEK139.0M ) aşmaktadır.

Borç-Özkaynak Tarihçesi ve Analizi

Borç Seviyesi: ONCO şirketinin toplam borcundan daha fazla nakiti var.

Borcun Azaltılması: ONCO şirketinin borç/öz sermaye oranı son 5 yılda 0% seviyesinden 59.5% seviyesine yükseldi.

Bilanço

Nakit Pist Analizi

Geçmişte ortalama olarak zarar eden şirketler için, en az 1 yıllık nakit akışına sahip olup olmadıklarını değerlendiriyoruz.

İstikrarlı Nakit Pisti: ONCO şirketinin mevcut serbest nakit akışına göre bir yıldan fazla yetecek nakit pisti bulunmaktadır.

Tahmini Nakit Akışı: ONCO serbest nakit akışı her yıl % 2.8 oranında tarihsel oranda büyümeye devam ederse 3 yıldan fazla bir süre için yeterli nakit akışına sahip olur

Oncopeptides Bilanço Sağlığı

Finansal Sağlık kriter kontrolleri 5/6

Anahtar bilgiler

Son finansal sağlık güncellemeleri

Oncopeptides (STO:ONCO) Will Have To Spend Its Cash Wisely

Oncopeptides (STO:ONCO) Has Debt But No Earnings; Should You Worry?

We Think Oncopeptides (STO:ONCO) Needs To Drive Business Growth Carefully

Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?

Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?

Recent updates

Consensus revenue estimates decrease by 34%, EPS upgraded

Price target decreased by 29% to kr4.33

Second quarter 2024 earnings released: kr0.48 loss per share (vs kr0.60 loss in 2Q 2023)

Consensus revenue estimates fall by 11%

An undisclosed buyer acquired an 9.166336% stake in Oncopeptides AB (publ) (OM:ONCO) from Industrifonden for SEK 22.4 million.

An Intrinsic Calculation For Oncopeptides AB (publ) (STO:ONCO) Suggests It's 45% Undervalued

Consensus EPS estimates fall by 34%, revenue upgraded

First quarter 2024 earnings released: kr0.75 loss per share (vs kr0.75 loss in 1Q 2023)

Oncopeptides AB (publ) Presents New Data Highlighting Treatment Benefits of Pepaxti in High-Risk Multiple Myeloma Patients at the COMy Congress

New major risk - Shareholder dilution

Price target decreased by 7.2% to kr6.40

Consensus EPS estimates fall by 38%

Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024

Oncopeptides AB (Publ) Provides Sales Guidance for the First Quarter of 2024

Oncopeptides AB (publ) has filed a Follow-on Equity Offering in the amount of SEK 300 million.

Oncopeptides (STO:ONCO) Will Have To Spend Its Cash Wisely

New major risk - Financial position

Oncopeptides AB (publ), Annual General Meeting, May 22, 2024

Oncopeptides Announces European Commission Decides to Formally Approve its Application to EMA for Extended Indication for Pepaxti into Earlier Lines

Oncopeptides AB (publ) to Report Q3, 2024 Results on Nov 07, 2024

Oncopeptides Selects to Present Additional Data from Ocean Study

Oncopeptides (STO:ONCO) Has Debt But No Earnings; Should You Worry?

Oncopeptides AB (publ) to Report Q2, 2024 Results on Aug 14, 2024

Oncopeptides AB (publ) Announces the Nomination Committee

Oncopeptides AB (publ) to Report Q1, 2024 Results on May 03, 2024

Oncopeptides AB (publ) to Report Fiscal Year 2023 Final Results on Apr 22, 2024

Oncopeptides AB (publ) to Report Fiscal Year 2023 Results on Feb 27, 2024

Oncopeptides AB (Publ) Announces Positive Opinion on Type II Variation to Extend the Therapeutic Indication of Pepaxti Based on Ocean Trial Results

Consensus revenue estimates increase by 47%

Oncopeptides AB (publ) Appoints Henrik Bergentoft as Chief Financial Officer

Oncopeptides AB (publ) Announces Sofia Heigis to Move from the CCO Role to CEO Role

We Think Oncopeptides (STO:ONCO) Needs To Drive Business Growth Carefully

Holger Lembrér Will Leave Oncopeptides as Chief Financial Officer

Consensus revenue estimates decrease by 11%, EPS upgraded

No longer forecast to breakeven

Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?

Oncopeptides AB (publ) to Report Q2, 2023 Results on Aug 10, 2023

Full year 2022 earnings released: kr4.11 loss per share (vs kr19.00 loss in FY 2021)

Forecast to breakeven in 2024

Oncopeptides AB (Publ) Announces Chief Financial Officer Changes

Oncopeptides AB (publ) Announces Jakob Lindberg Assumes Chief Scientific Officer

Oncopeptides AB (Publ) Announces Executive Changes

Oncopeptides AB (publ) Announces Nomination Committee Appointments

Oncopeptides AB (publ) to Report Fiscal Year 2022 Final Results on Apr 25, 2023

Oncopeptides Provides Update on Pepaxto US Marketing Authorization

Is Oncopeptides (STO:ONCO) In A Good Position To Invest In Growth?

Price target decreased to kr22.50

Consensus revenue estimates fall by 76%

Insufficient new directors

Oncopeptides AB (Publ) Announces Pepaxti Has Been Granted Marketing Authorization in the Uk

Oncopeptides AB (Publ) Announces the Market Potential for Pepaxti in Europe

Forecast to breakeven in 2024

Oncopeptides AB (publ), Annual General Meeting, May 25, 2023

Oncopeptides AB (publ) Announces Data from the Phase 3 Lighthouse Study

Consensus revenue estimates fall by 30%

Oncopeptides AB (publ) Starts Commercialization of Pepaxti in Europe - Germany First Market

Consensus revenue estimates fall by 36%

Oncopeptides AB (publ) Provides Update from Meeting with Advisory Committee ODAC

Oncopeptides AB (Publ) Receives SEK 5 Million Grant for Nk-Cell Engager Project in Multiple Myeloma

European Commission Approves Oncopeptides' Pepaxti for the Treatment of Patients with Relapsed Refractory Multiple Myeloma

Consensus revenue estimates increase by 243%

Oncopeptides AB (Publ) Issues A Positive Opinion Recommending Full Approval of Oncopeptides Peti in Eu for Patients with Tr Triple Class Refractory Multiple Myeloma

Consensus revenue estimates increase by 89%

Oncopeptides AB (Publ) Announces That the European Medicines Agency´S Committee for Medicinal Products for Human Use

Price target increased to kr11.15

Consensus forecasts updated

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

No longer forecast to breakeven

Insufficient new directors

Chief Executive Officer recently bought kr2.0m worth of stock